Drug recall · May 4, 2022
Insulin Glargine recall
Why: Labeling: Missing label on the vial
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a 10 mL Multiple-Dose vial inside a carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505, NDC 49502-393-80
- Lots / codes
Lot #: BF21002800, Exp 8/2023
- Quantity
- 89,665 vials
- Company
- Mylan Pharmaceuticals Inc, Morgantown, WV
- Distribution
- USA nationwide.
- Initiated
- April 12, 2022 · Voluntary: Firm initiated
- Classified
- May 4, 2022
- Reported
- May 4, 2022
- Ended
- October 18, 2023
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Insulin glargine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.